Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 3, 2017, Pages 486-491

  Sevrioukova, Irina F ^a   Poulos, Thomas L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crystal structure; CYP3A4; Drug metabolism; Midazolam; Substrate binding

Indexed keywords

ALPHA NAPHTHOFLAVONE; CARBAMAZEPINE; CYTOCHROME P450 3A4; HYDROGEN; MIDAZOLAM; SERINE; TESTOSTERONE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; HYPNOTIC SEDATIVE AGENT; RECOMBINANT PROTEIN;

ALLELE; ATOM; COMPUTER MODEL; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG CONFORMATION; DRUG HYDROXYLATION; DRUG OXIDATION; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME IMMOBILIZATION; ENZYME SUBSTRATE COMPLEX; GENETIC VARIATION; HUMAN; HYDROGEN BOND; IONIC STRENGTH; MOLECULAR DYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; AMINO ACID SUBSTITUTION; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME SPECIFICITY; GENETICS; METABOLISM; MOLECULAR MODEL; OSMOLARITY; OXIDATION REDUCTION REACTION; PROTEIN CONFORMATION; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SUBSTITUTION; BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 CYP3A; HUMANS; HYDROGEN BONDING; HYPNOTICS AND SEDATIVES; MIDAZOLAM; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; OSMOLAR CONCENTRATION; OXIDATION-REDUCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 85009799034     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1616198114     Document Type: Article

References (30)

1. Guengerich FP (1999) Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
2. Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29(1-2): 413-580.
3. Atkins WM (2005) Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. Annu Rev Pharmacol Toxicol 45:291-310.
4. Yano JK, et al. (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279(37): 38091-38094.
5. Williams PA, et al. (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305(5684):683-686.
6. Ekroos M, Sjögren T (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA 103(37):13682-13687.
7. Sevrioukova IF, Poulos TL (2012) Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand. J Biol Chem 287(5):3510-3517.
8. Sevrioukova IF, Poulos TL (2015) Anion-dependent stimulation of CYP3A4 monooxygenase. Biochemistry 54(26):4083-4096.
9. Tobias JD, Leder M (2011) Procedural sedation: A review of sedative agents, monitoring, and management of complications. Saudi J Anaesth 5(4):395-410.
10. Thummel KE, Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
11. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47(9):1643-1653.
12. Mäenpää J, Hall SD, Ring BJ, Strom SC, Wrighton SA (1998) Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: The effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 8(2):137-155.
13. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab Dispos 24(9):940-947.
14. Roberts AG, et al. (2011) The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4. Biochemistry 50(50):10804-10818.
15. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY (2000) Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos 28(3):360-366.
16. Emoto C, Murayama N, Yamazaki H (2008) Effects of enzyme sources on midazolam 1'-hydroxylation activity catalyzed by recombinant cytochrome P450 3A4 in combination with NADPH-cytochrome P450 reductase. Drug Metab Lett 2(3):190-192.
17. Cameron MD, et al. (2005) Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: A NMR T1 paramagnetic relaxation study. Biochemistry 44(43):14143-14151.
18. Hosea NA, Miller GP, Guengerich FP (2000) Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39(20):5929-5939.
19. Schrag ML, Wienkers LC (2001) Covalent alteration of the CYP3A4 active site: Evidence for multiple substrate binding domains. Arch Biochem Biophys 391(1):49-55.
20. Sevrioukova IF, Poulos TL (2015) Current approaches for investigating and predicting cytochrome P450 3A4-ligand interactions. Adv Exp Med Biol 851:83-105.
21. Khan KK, He YQ, Domanski TL, Halpert JR (2002) Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: An evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61(3):495-506.
22. Roussel F, Khan KK, Halpert JR (2000) The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4. Arch Biochem Biophys 374(2):269-278.
23. Eiselt R, et al. (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11(5):447-458.
24. Werk AN, Cascorbi I (2014) Functional gene variants of CYP3A4. Clin Pharmacol Ther 96(3):340-348.
25. Maekawa K, et al. (2009) Functional characterization of CYP3A4.16: Catalytic activities toward midazolam and carbamazepine. Xenobiotica 39(2):140-147.
26. Kang YS, et al. (2009) The CYP3A4∗18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 85(3):312-318.
27. Ueng YF, Kuwabara T, Chun YJ, Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36(2):370-381.
28. Sevrioukova IF, Poulos TL (2013) Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir. J Med Chem 56(9):3733-3741.
29. Winn MD, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67(Pt 4):235-242.
30. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66(Pt 4):486-501.